Company Everest Medicines Limited

1952

KYG3224E1061

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for Everest Medicines Limited

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Biopharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:09:09 2024-04-25 am EDT			5-day change	1st Jan Change
24.1 ^HKD	+2.55%		+5.24%	+15.31%

Apr. 25	Everest Medicines' Loss Widens in 2023	MT
Mar. 28	Everest Medicines Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Everest Medicines Ltd is a China-based company principally engaged in the licensing, clinical development and commercialization of therapies to address critical unmet medical needs. The Company is focusing on the research and development of innovative drug candidate. The Company built a portfolio of promising clinical-stage drug candidates across oncology, immunology, cardio-renal disease and infectious disease. The Company mainly provides its products and services in Greater China and other emerging Asia Pacific markets.

Number of employees: 432

HKD in Million	2022	Weight	2023	Weight	Delta
Pharmaceutical 100.0 %	15	100.0 %	139	100.0 %	+835.46%

HKD in Million	2022	Weight	2023	Weight	Delta
Singapore 100.0 %	15	100.0 %	139	100.0 %	+835.46%

Managers	Title	Age	Since
Yong Qing Luo CEO	Chief Executive Officer	54	22-09-18
Ian Ying Woo PSD	President	51	18-11-30
Michael Berry CTO	Chief Tech/Sci/R&D Officer	59	23-06-14
Jennifer Yang CTO	Chief Tech/Sci/R&D Officer	56	21-04-14
Xu Xin Liu IRC	Investor Relations Contact	40	21-09-30
Yang Shi PRN	Corporate Officer/Principal	48	19-01-31
Zhengying Zhu PRN	Corporate Officer/Principal	51	17-10-31
Xu Zhu PRN	Corporate Officer/Principal	54	17-09-30
Yee Wa Lau SEC	Corporate Secretary	52	-
Jason M. Brown PRN	Corporate Officer/Principal	52	17-06-30

Members of the board	Title	Age	Since
Yi Fan Li BRD	Director/Board Member	55	20-08-31
Honggang Feng BRD	Director/Board Member	59	Feb. 08
Wei Fu CHM	Chairman	42	17-06-30
Ki Chul Cho BRD	Director/Board Member	46	Jan. 11
Ian Ying Woo PSD	President	51	18-11-30
Shi Dong Jiang BRD	Director/Board Member	57	20-08-31
Yong Qing Luo CEO	Chief Executive Officer	54	22-09-18
Hoi Yam Chui BRD	Director/Board Member	57	23-01-18

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	324,183,348	193,532,752 ( 59.70 %)	0	59.70 %

Name	Equities	%	Valuation
CBC Group (Singapore) Pte. Ltd. 39.90 %	129,265,877	39.90 %	388 M $
Wei Fu 6.922 %	22,425,617	6.922 %	67 M $
Janchor Partners Ltd. 4.900 %	15,875,944	4.900 %	48 M $
RA Capital Management LP 4.698 %	15,219,811	4.698 %	46 M $
Kerry Levan Blanchard 2.430 %	7,873,499	2.430 %	24 M $
Decheng Capital LLC 1.286 %	4,166,667	1.286 %	13 M $
Xiaofan Zhang 1.191 %	3,858,630	1.191 %	12 M $
Bosera Asset Management Co., Ltd. 0.3695 %	1,197,000	0.3695 %	4 M $
Yong Qing Luo 0.3026 %	980,474	0.3026 %	3 M $
Ian Ying Woo 0.0625 %	202,589	0.0625 %	608 302 $

Everest Medicines Ltd.

CITIC Pacific Plaza 1168 West Nanjing Road

200041, Shanghai

http://www.everestmedicines.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

22.3 CNY

Average target price

25.92 CNY

Spread / Average Target

+16.21%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Biopharmaceuticals

	1st Jan change	Capi.
EVEREST MEDICINES LIMITED	+15.31%	960M
CSL LIMITED	-2.86%	87.31B
SAMSUNG BIOLOGICS CO.,LTD.	+2.63%	40.86B
BIOGEN INC.	-21.76%	29.36B
UCB	+58.56%	24.49B
BIOMARIN PHARMACEUTICAL INC.	-14.78%	17.31B
INCYTE CORPORATION	-18.49%	11.62B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-15.61%	11.31B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.02%	11.26B
SWEDISH ORPHAN BIOVITRUM AB	+5.17%	8.31B

Biopharmaceuticals